Triple-Negative Breast Cancer: A Brief Review About Epidemiology, Risk Factors, Signaling Pathways, Treatment and Role of Artificial Intelligence

Overview

Journal Front Mol Biosci

Specialty Biology

Date 2022 Feb 11

PMID 35145999

Authors

Nahlah Makki Almansour

Affiliations

Soon will be listed here.

Abstract

Triple-negative breast cancer (TNBC) is a kind of breast cancer that lacks estrogen, progesterone, and human epidermal growth factor receptor 2. This cancer is responsible for more than 15-20% of all breast cancers and is of particular research interest as it is therapeutically challenging mainly because of its low response to therapeutics and highly invasive nature. The non-availability of specific treatment options for TNBC is usually managed by conventional therapy, which often leads to relapse. The focus of this review is to provide up-to-date information related to TNBC epidemiology, risk factors, metastasis, different signaling pathways, and the pathways that can be blocked, immune suppressive cells of the TNBC microenvironment, current and investigation therapies, prognosis, and the role of artificial intelligence in TNBC diagnosis. The data presented in this paper may be helpful for researchers working in the field to obtain general and particular information to advance the understanding of TNBC and provide suitable disease management in the future.

Citing Articles

Bioinformatics-Driven Investigations of Signature Biomarkers for Triple-Negative Breast Cancer.

Handa S, Puri S, Chatterjee M, Puri V Bioinform Biol Insights. 2025; 19:11779322241271565.

PMID: 40034579 PMC: 11873876. DOI: 10.1177/11779322241271565.

Engineered zwitterionic diblock copolymer-siRNA polyplexes provide highly effective treatment of triple-negative breast cancer in a 4T1 murine model.

Jeon T, Goswami R, Nagaraj H, Cicek Y, Lehot V, Welton J Adv Funct Mater. 2025; 34(42).

PMID: 40017807 PMC: 11864752. DOI: 10.1002/adfm.202406763.

The Relationship Between KI67 Expression and Grading with Chemotherapy Response in Triple-Negative Breast Cancer Patients at Haji Adam Malik General Hospital, Medan.

Putra E, Hermansyah D, Pasaribu E, Eyanoer P Med Arch. 2025; 78(4):285-289.

PMID: 39981154 PMC: 11838830. DOI: 10.5455/medarh.2024.78.285-289.

Mind relaxation effect of Jatamansi Taila Shirodhara on psychological distress in Triple Negative Breast Cancer patients - results of an open-labelled, randomised controlled clinical trial.

Sardeshmukh S, Deshmukh V, Godse V, Pathrikar A, Joshi A, Gujar S J Ayurveda Integr Med. 2025; 16(1):101069.

PMID: 39874651 PMC: 11831738. DOI: 10.1016/j.jaim.2024.101069.

Ethanolic Extract of Leaf Has an Anticancer Activity on Triple-Negative Breast Cancer Cells: An In Vitro Study.

Beas-Guzman O, Cabrera-Licona A, Hernandez-Fuentes G, Ceballos-Magana S, Guzman-Esquivel J, De-Leon-Zaragoza L Pharmaceutics. 2025; 17(1).

PMID: 39861654 PMC: 11768879. DOI: 10.3390/pharmaceutics17010002.

References

De Vos M, Schreiber V, Dantzer F . The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem Pharmacol. 2012; 84(2):137-46. DOI: 10.1016/j.bcp.2012.03.018. View

Giancotti F . Mechanisms governing metastatic dormancy and reactivation. Cell. 2013; 155(4):750-64. PMC: 4354734. DOI: 10.1016/j.cell.2013.10.029. View

Michalet X, Pinaud F, Bentolila L, Tsay J, Doose S, Li J . Quantum dots for live cells, in vivo imaging, and diagnostics. Science. 2005; 307(5709):538-44. PMC: 1201471. DOI: 10.1126/science.1104274. View

Kuroda H, Jamiyan T, Yamaguchi R, Kakumoto A, Abe A, Harada O . Tumor microenvironment in triple-negative breast cancer: the correlation of tumor-associated macrophages and tumor-infiltrating lymphocytes. Clin Transl Oncol. 2021; 23(12):2513-2525. PMC: 8557183. DOI: 10.1007/s12094-021-02652-3. View

Eccles S . The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology. Int J Dev Biol. 2011; 55(7-9):685-96. DOI: 10.1387/ijdb.113396se. View

Balaji K, Subramanian B, Yadav P, Anu Radha C, Ramasubramanian V . Radiation therapy for breast cancer: Literature review. Med Dosim. 2016; 41(3):253-7. DOI: 10.1016/j.meddos.2016.06.005. View

Ghoncheh M, Pournamdar Z, Salehiniya H . Incidence and Mortality and Epidemiology of Breast Cancer in the World. Asian Pac J Cancer Prev. 2016; 17(S3):43-6. DOI: 10.7314/apjcp.2016.17.s3.43. View

Schmid P, Adams S, Rugo H, Schneeweiss A, Barrios C, Iwata H . Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018; 379(22):2108-2121. DOI: 10.1056/NEJMoa1809615. View

Dudley J, Lin M, Le D, Eshleman J . Microsatellite Instability as a Biomarker for PD-1 Blockade. Clin Cancer Res. 2016; 22(4):813-20. DOI: 10.1158/1078-0432.CCR-15-1678. View

10.

Fatima Z, Guo P, Huang D, Lu Q, Wu Q, Dai M . The critical role of p16/Rb pathway in the inhibition of GH3 cell cycle induced by T-2 toxin. Toxicology. 2018; 400-401:28-39. DOI: 10.1016/j.tox.2018.03.006. View

11.

Muneer I, Ahmad S, Naz A, Abbasi S, Alblihy A, Aloliqi A . Discovery of Novel Inhibitors From Medicinal Plants for V-Domain Ig Suppressor of T-Cell Activation. Front Mol Biosci. 2021; 8:716735. PMC: 8576517. DOI: 10.3389/fmolb.2021.716735. View

12.

Sobande F, Dusek L, Matejkova A, Rozkos T, Laco J, Ryska A . EGFR in triple negative breast carcinoma: significance of protein expression and high gene copy number. Cesk Patol. 2015; 51(2):80-6. View

13.

Carey L, Rugo H, Marcom P, Mayer E, Esteva F, Ma C . TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012; 30(21):2615-23. PMC: 3413275. DOI: 10.1200/JCO.2010.34.5579. View

14.

Leso V, Luigia Ercolano M, Cioffi D, Iavicoli I . Occupational Chemical Exposure and Breast Cancer Risk According to Hormone Receptor Status: A Systematic Review. Cancers (Basel). 2019; 11(12). PMC: 6966433. DOI: 10.3390/cancers11121882. View

15.

Protani M, Coory M, Martin J . Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2010; 123(3):627-35. DOI: 10.1007/s10549-010-0990-0. View

16.

Jamdade V, Sethi N, Mundhe N, Kumar P, Lahkar M, Sinha N . Therapeutic targets of triple-negative breast cancer: a review. Br J Pharmacol. 2015; 172(17):4228-37. PMC: 4556464. DOI: 10.1111/bph.13211. View

17.

Park S, Chen A . Poly(Adenosine diphosphate-ribose) polymerase inhibitors in cancer treatment. Hematol Oncol Clin North Am. 2012; 26(3):649-70, ix. PMC: 3600582. DOI: 10.1016/j.hoc.2012.02.012. View

18.

Muneer I, Ul Qamar M, Tusleem K, Rauf S, Hussain H, Siddiqi A . Discovery of selective inhibitors for cyclic AMP response element-binding protein: a combined ligand and structure-based resources pipeline. Anticancer Drugs. 2018; 30(4):363-373. DOI: 10.1097/CAD.0000000000000727. View

19.

Murai J, Huang S, Das B, Renaud A, Zhang Y, Doroshow J . Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012; 72(21):5588-99. PMC: 3528345. DOI: 10.1158/0008-5472.CAN-12-2753. View

20.

Nabholtz J, Abrial C, Mouret-Reynier M, Dauplat M, Weber B, Gligorov J . Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact. Ann Oncol. 2014; 25(8):1570-7. DOI: 10.1093/annonc/mdu183. View